Literature DB >> 22247956

A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors.

Kevin X Chen1, Charles A Lesburg, Bancha Vibulbhan, Weiying Yang, Tin-Yau Chan, Srikanth Venkatraman, Francisco Velazquez, Qingbei Zeng, Frank Bennett, Gopinadhan N Anilkumar, Jose Duca, Yueheng Jiang, Patrick Pinto, Li Wang, Yuhua Huang, Oleg Selyutin, Stephen Gavalas, Haiyan Pu, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A Kozlowski, Stuart B Rosenblum, F George Njoroge.   

Abstract

Starting from indole-based C-3 pyridone HCV NS5B polymerase inhibitor 2, structure-activity relationship (SAR) investigations of the indole N-1 benzyl moiety were performed. This study led to the discovery of irreversible inhibitors with p-fluoro-sulfone- or p-fluoro-nitro-substituted N-1 benzyl groups which achieved breakthrough replicon assay potency (EC(50) = 1 nM). The formation of a covalent bond with adjacent cysteine-366 thiol was was proved by mass spectroscopy and X-ray crystal structure studies. The C-5 ethyl C-2 carboxylic acid derivative 47 had an excellent oral area-under-the-curve (AUC) of 18 μM·h (10 mg/kg). Its oral exposure in monkeys and dogs was also very good. The NMR ALARM assay, mass spectroscopy experiments, in vitro counter screening, and toxicology assays demonstrated that the covalent bond formation between compound 47 and the protein was highly selective and specific. The overall excellent profile of 47 made it an interesting candidate for further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22247956     DOI: 10.1021/jm201322r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

2.  Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Authors:  Robin A Fairhurst; Thomas Knoepfel; Catherine Leblanc; Nicole Buschmann; Christoph Gaul; Jutta Blank; Inga Galuba; Jörg Trappe; Chao Zou; Johannes Voshol; Christine Genick; Peggy Brunet-Lefeuvre; Francis Bitsch; Diana Graus-Porta; Pascal Furet
Journal:  Medchemcomm       Date:  2017-06-08       Impact factor: 3.597

3.  The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.

Authors:  Christy M Hebner; Bin Han; Katherine M Brendza; Michelle Nash; Maisoun Sulfab; Yang Tian; Magdeleine Hung; Wanchi Fung; Randall W Vivian; James Trenkle; James Taylor; Kyla Bjornson; Steven Bondy; Xiaohong Liu; John Link; Johan Neyts; Roman Sakowicz; Weidong Zhong; Hengli Tang; Uli Schmitz
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

4.  Targeting HCV polymerase: a structural and dynamic perspective into the mechanism of selective covalent inhibition.

Authors:  Letitia Shunmugam; Mahmoud E S Soliman
Journal:  RSC Adv       Date:  2018-12-18       Impact factor: 4.036

5.  Classification of HCV NS5B polymerase inhibitors using support vector machine.

Authors:  Maolin Wang; Kai Wang; Aixia Yan; Changyuan Yu
Journal:  Int J Mol Sci       Date:  2012-03-27       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.